Quote:

---

Amarantus anticipates reporting final top-line data of its LP-002 clinical study to assess LymPro's predictive value in diagnosing mild to severe Alzheimer's disease patients by the end of 2014.

(only 6 trading days left - why run it down to the wire)

Amarantus intends to publish data from this study, as well as previously reported data, at prestigious scientific congresses and in peer-reviewed journals throughout the course of 2015.

This additional data will then be useful in making a determination regarding which version of LymPro (V-1 or V-2) Amarantus will launch under the CLIA designation for marketing to the broader medical community in the US in 2015.

(final selection taking much longer than initially suspected)

---